Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
华夏幸福 散户数量 -28.38 含义
Type of publications
Guidelines (40)
NITAG documentation (1628)
Reports (60)
SAGE documentation (226)
Scientific publications (120)
Systematic reviews (SYSVAC) (2972)
Regions
Africa (292)
Americas (783)
Eastern Mediterranean (57)
Europe (731)
Global (1)
South-East Asia (81)
Western Pacific (210)
Diseases
Chikungunya (11)
Cholera (35)
COVID-19 (1552)
Cytomegalovirus (1)
Dengue (41)
Diphtheria (83)
Ebola (17)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (69)
Hepatitis A (65)
Hepatitis B (164)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (73)
HIV / AIDS (10)
Human papillomavirus (HPV) (515)
Influenza (610)
Japanese encephalitis (34)
Lyme disease, Borreliosis (2)
Malaria (31)
Measles (139)
Meningococcal disease (152)
Moraxella catarrhalis (1)
Mpox (56)
Mumps (47)
Pertussis (113)
Pneumococcal disease (292)
Poliomyelitis (89)
Q fever (1)
Rabies (32)
Rotavirus (117)
RSV (Respiratory syncytial virus) (60)
Rubella (66)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (64)
Tick-borne encephalitis (12)
Tuberculosis (79)
Typhoid (27)
Varicella (75)
Yellow fever (44)
Zika (1)
Show more
5046 results found
2025
Use of the bivalent respiratory syncytial virus (RSV) vaccine (Abrysvo™, Pfizer) during pregnancy for the prevention of RSV–associated lower respiratory tract disease in Infants
2025
Update to the document “Evaluation of RSV vaccination in the adult population”
2025
Vaccination against pneumococcal disease in adults (revision 2025)
2025
Table 1: Summary of WHO Position Papers - Recommendations for Routine Immunization
2025
Improved influenza vaccines: full value vaccine assessment
2025
6th GNN meeting record of discussion
2025
∙
WHO AFRO
Mpox vaccination toolkit
2025
Frequently Asked Questions (FAQ) on use of fractional dosing with intradermal administration of mpox MVA-BN vaccine in the context of vaccine supply-constrained outbreak response
2025
∙
SAGE
WHO guidance on the use of licensed human influenza A(H5) vaccines for the interpandemic and emergence periods
2025
∙
National Advisory Group on Immunisation (NAGI)
RSV vaccination recommendation during pregnancy
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register